person · Reporting owner

PEARSON TIMOTHY R

Disclosed activity across 4 companies

Tapewire entity: 39174
SEC CIK: 0001528617

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRESCENT BIOPHARMA, INC.GLYC · Entity 5255	Director	May 01, 2024	May 01, 2024
Korro Bio, Inc.KRRO · Entity 6388	Director	June 10, 2026	June 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRESCENT BIOPHARMA, INC.

Report date May 01, 2024 · Filed May 01, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2034-04-30	Direct	40,000	Reported balance After 2024-05-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-05-01 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

Korro Bio, Inc.

Report date June 10, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 · Expires 2036-06-09	Direct	14,677	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 14,677 · Balance 14,677 F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Ra Pharmaceuticals, Inc.

Report date April 02, 2020 · Filed April 03, 2020

Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2026-03-10	Direct	Reported balance After 2020-04-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-04-02 · Disposition to issuer · Disposed 22,857 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.37 · Expires 2027-06-20	Direct	Reported balance After 2020-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.90 · Expires 2028-06-28	Direct	Reported balance After 2020-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.88 · Expires 2029-06-11	Direct	Reported balance After 2020-04-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.

F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.

TESARO, Inc.

Report date January 22, 2019 · Filed January 22, 2019

Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-01-22 transaction · row 1 1 source row Row 1 · 2019-01-22 · Other · Disposed 6,211 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-01-22 · Disposition to issuer · Disposed 8,750 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-01-22 · Disposition to issuer · Disposed 4,447 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-01-22 · Disposition to issuer · Disposed 18,182 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.27 · Expires 2024-05-27	Direct	Reported balance After 2019-01-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-01-22 · Disposition to issuer · Disposed 125,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.11 · Expires 2025-03-06	Direct	Reported balance After 2019-01-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-01-22 · Disposition to issuer · Disposed 55,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.39 · Expires 2026-03-01	Direct	Reported balance After 2019-01-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-01-22 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $178.95 · Expires 2027-03-01	Direct	Reported balance After 2019-01-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-01-22 · Disposition to issuer · Disposed 10,782 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2028-03-01	Direct	Reported balance After 2019-01-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-01-22 · Disposition to issuer · Disposed 31,954 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Filing footnotes · ownership attribution and instrument terms

F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").

F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2026 Filed Jun 11, 2026 21:55 UTC	Korro Bio, Inc. KRRO · Entity 6388	GrantStock Option (Right to Buy) · Derivative	14,677	$0.00 Strike: $10.59	$0.00	Disclosure SEC source: 0001193125-26-267993 · ownership.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,677 Underlying: Common Stock · 14,677 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. Read SEC document
June 11, 2025 Filed Jun 12, 2025 20:20 UTC	Korro Bio, Inc. KRRO · Entity 6388	GrantStock Option (Right to Buy) · Derivative	6,010	$0.00 Strike: $14.87	$0.00	Disclosure SEC source: 0000950170-25-085411 · ownership.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,010 Underlying: Common Stock · 6,010 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. Read SEC document
June 11, 2024 Filed Jun 12, 2024 21:17 UTC	Korro Bio, Inc. KRRO · Entity 6388	GrantStock Option (Right to Buy) · Derivative	5,190	$0.00 Strike: $42.19	$0.00	Disclosure SEC source: 0000950170-24-072556 · ownership.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,190 Underlying: Common Stock · 5,190 shares Expires 2034-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. Read SEC document
May 01, 2024 Filed May 1, 2024 20:29 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $1.62	$0.00	Disclosure SEC source: 0001415889-24-011867 · form4-05012024_080504.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date. Read SEC document
November 03, 2023 Filed Nov 8, 2023 02:10 UTC	Korro Bio, Inc. KRRO · Entity 6388	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $14.98	$0.00	Disclosure SEC source: 0000950170-23-060599 · ownership.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-11-02 F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
May 19, 2023 Filed May 22, 2023 20:21 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	35,000	$0.00 Strike: $1.98	$0.00	Disclosure SEC source: 0001209191-23-031451 · doc4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares underlying this option vest on May 19, 2024, subject to the reporting person's continuous service as of such vesting date. Read SEC document
November 11, 2022 Filed Nov 14, 2022 21:14 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	PurchaseCommon Stock	19,400	$1.29	$25,026.00	Disclosure SEC source: 0001209191-22-056587 · doc4.xml · nonDerivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,650 Read SEC document
May 18, 2022 Filed May 20, 2022 20:20 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	21,000	$0.00 Strike: $0.60	$0.00	Disclosure SEC source: 0001209191-22-031010 · doc4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document
May 18, 2021 Filed May 28, 2021 00:47 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	10,500	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001209191-21-036373 · doc4.xml · derivative · entry 2 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document
May 18, 2021 Filed May 28, 2021 00:47 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantCommon Stock	5,250	$0.00	$0.00	Disclosure SEC source: 0001209191-21-036373 · doc4.xml · nonDerivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document
May 22, 2020 Filed May 27, 2020 20:32 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	21,000	$0.00 Strike: $3.00	$0.00	Disclosure SEC source: 0001209191-20-032311 · doc4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The shares underlying this option vest on May 22, 2021, subject to the reporting person's continuous service as of such vesting date. Read SEC document
April 02, 2020 Filed Apr 3, 2020 09:01 UTC	Ra Pharmaceuticals, Inc. RARX · Entity 150034	Disposition to issuerStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $19.88	$0.00	Disclosure SEC source: 0001104659-20-042767 · a4.xml · derivative · entry 4 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-06-11 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document
April 02, 2020 Filed Apr 3, 2020 09:01 UTC	Ra Pharmaceuticals, Inc. RARX · Entity 150034	Disposition to issuerStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $9.90	$0.00	Disclosure SEC source: 0001104659-20-042767 · a4.xml · derivative · entry 3 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2028-06-28 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document
April 02, 2020 Filed Apr 3, 2020 09:01 UTC	Ra Pharmaceuticals, Inc. RARX · Entity 150034	Disposition to issuerStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $22.37	$0.00	Disclosure SEC source: 0001104659-20-042767 · a4.xml · derivative · entry 2 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-06-20 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document
April 02, 2020 Filed Apr 3, 2020 09:01 UTC	Ra Pharmaceuticals, Inc. RARX · Entity 150034	Disposition to issuerStock Option (Right to Buy) · Derivative	22,857	$0.00 Strike: $2.87	$0.00	Disclosure SEC source: 0001104659-20-042767 · a4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,857 shares Expires 2026-03-10 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document
June 11, 2019 Filed Jun 13, 2019 16:35 UTC	Ra Pharmaceuticals, Inc. RARX · Entity 150034	GrantOption to Purchase Common Stock · Derivative	15,000	$0.00 Strike: $19.88	$0.00	Disclosure SEC source: 0001104659-19-035364 · a4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: On June 11, 2019, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the first anniversary of the grant date of June 11, 2019 or (ii) the Issuer's annual meeting of shareholders in 2020. Read SEC document
May 17, 2019 Filed May 21, 2019 20:06 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantCommon Stock · Derivative	21,000	$0.00 Strike: $12.39	$0.00	Disclosure SEC source: 0001209191-19-031718 · doc4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares underlying this option vest on May 17, 2020, subject to the reporting person's continuous service as of such vesting date. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	31,954	Not disclosed Strike: $55.84	Not disclosed	Disclosure SEC source: 0001123292-19-000173 · edgar.xml · derivative · entry 9 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,954 shares Expires 2028-03-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	10,782	Not disclosed Strike: $178.95	Not disclosed	Disclosure SEC source: 0001123292-19-000173 · edgar.xml · derivative · entry 8 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,782 shares Expires 2027-03-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	35,000	Not disclosed Strike: $43.39	Not disclosed	Disclosure SEC source: 0001123292-19-000173 · edgar.xml · derivative · entry 7 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2026-03-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	55,000	Not disclosed Strike: $55.11	Not disclosed	Disclosure SEC source: 0001123292-19-000173 · edgar.xml · derivative · entry 6 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2025-03-06 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	125,000	Not disclosed Strike: $25.27	Not disclosed	Disclosure SEC source: 0001123292-19-000173 · edgar.xml · derivative · entry 5 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2024-05-27 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerRestricted Stock Units · Derivative	18,182	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000173 · edgar.xml · derivative · entry 4 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,182 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerRestricted Stock Units · Derivative	4,447	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000173 · edgar.xml · derivative · entry 3 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,447 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerRestricted Stock Units · Derivative	8,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000173 · edgar.xml · derivative · entry 2 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	6,211	$75.00	$465,825.00	Disclosure SEC source: 0001123292-19-000173 · edgar.xml · nonDerivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). Read SEC document
June 28, 2018 Filed Jul 2, 2018 07:25 UTC	Ra Pharmaceuticals, Inc. RARX · Entity 150034	GrantOptions to Purchase Common Stock · Derivative	15,000	$0.00 Strike: $9.90	$0.00	Disclosure SEC source: 0001104659-18-043344 · a4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-28 F1 · derivative.exercise_date: On June 28, 2018, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the first anniversary of the grant date of June 28, 2018 or (ii) the Issuer's annual meeting of shareholders in 2019. Read SEC document
May 18, 2018 Filed May 21, 2018 20:16 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $18.41	$0.00	Disclosure SEC source: 0001209191-18-031817 · doc4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2019, subject to the reporting person's continuous service as of such vesting date. Read SEC document
March 02, 2018 Filed Mar 5, 2018 17:23 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	2,575	$54.86	$141,264.50	Disclosure SEC source: 0001104659-18-014881 · a4.xml · nonDerivative · entry 3 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,211 F1 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. F2 · price: The price reported is a weighted average. The shares were sold in multiple transactions at prices ranging from $54.38 to $54.87, inclusive. The reporting person undertakes to provide to TESARO, any security holder of TESARO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:23 UTC	TESARO, Inc. TSRO · Entity 160894	GrantEmployee Stock Option (right to buy) · Derivative	31,954	$0.00 Strike: $55.84	$0.00	Disclosure SEC source: 0001104659-18-014881 · a4.xml · derivative · entry 7 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,954 Underlying: Common Stock · 31,954 shares Expires 2028-03-01 F7 · derivative.exercise_date: The option vests in 48 equal monthly installments beginning on April 1, 2018. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:23 UTC	TESARO, Inc. TSRO · Entity 160894	GrantRestricted Stock Units · Derivative	18,182	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014881 · a4.xml · derivative · entry 6 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,182 Underlying: Common Stock · 18,182 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F6 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on March 1, 2019. F6 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on March 1, 2019. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:23 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	1,483	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014881 · a4.xml · derivative · entry 5 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,447 Underlying: Common Stock · 1,483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F5 · derivative.exercise_date: The RSUs were granted on March 1, 2017, and the remaining RSUs vest in three equal annual installments on each of March 1, 2019, 2020 and 2021. F5 · derivative.expiration_date: The RSUs were granted on March 1, 2017, and the remaining RSUs vest in three equal annual installments on each of March 1, 2019, 2020 and 2021. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:23 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	4,375	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014881 · a4.xml · derivative · entry 4 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 4,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4 · derivative.exercise_date: The RSUs were granted on March 1, 2016, and the remaining RSUs vest in two equal annual installments on each of March 1, 2019 and 2020. F4 · derivative.expiration_date: The RSUs were granted on March 1, 2016, and the remaining RSUs vest in two equal annual installments on each of March 1, 2019 and 2020. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:23 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	1,483	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014881 · a4.xml · nonDerivative · entry 2 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:23 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	4,375	$0.00	$0.00	Disclosure SEC source: 0001104659-18-014881 · a4.xml · nonDerivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 20, 2017 Filed Jun 22, 2017 18:13 UTC	Ra Pharmaceuticals, Inc. RARX · Entity 150034	GrantOptions to Purchase Common Stock · Derivative	15,000	$0.00 Strike: $22.37	$0.00	Disclosure SEC source: 0001104659-17-040997 · a4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-20 F1 · derivative.exercise_date: On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018. Read SEC document
May 25, 2017 Filed May 30, 2017 20:10 UTC	CRESCENT BIOPHARMA, INC. GLYC · Entity 5255	GrantStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $13.89	$0.00	Disclosure SEC source: 0001209191-17-036121 · doc4.xml · derivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: The shares underlying this option vest on May 25, 2018, subject to the reporting person's continuous service as of such vesting date. Read SEC document
March 02, 2017 Filed Mar 3, 2017 17:19 UTC	TESARO, Inc. TSRO · Entity 160894	SaleCommon Stock	1,447	$177.61	$257,001.67	Disclosure SEC source: 0001104659-17-014116 · a4.xml · nonDerivative · entry 2 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,928 F1 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:19 UTC	TESARO, Inc. TSRO · Entity 160894	GrantEmployee Stock Option (right to buy) · Derivative	10,782	$0.00 Strike: $178.95	$0.00	Disclosure SEC source: 0001104659-17-014116 · a4.xml · derivative · entry 5 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,782 Underlying: Common Stock · 10,782 shares Expires 2027-03-01 F5 · derivative.exercise_date: The option vests in 48 equal monthly installments beginning on April 1, 2017. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:19 UTC	TESARO, Inc. TSRO · Entity 160894	GrantRestricted Stock Units · Derivative	5,930	$0.00	$0.00	Disclosure SEC source: 0001104659-17-014116 · a4.xml · derivative · entry 4 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,930 Underlying: Common Stock · 5,930 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2018. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2018. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:19 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionRestricted Stock Units · Derivative	4,375	$0.00	$0.00	Disclosure SEC source: 0001104659-17-014116 · a4.xml · derivative · entry 3 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 4,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · derivative.exercise_date: The restricted stock units were granted on March 1, 2016 and vest in four equal annual installments beginning on March 1, 2017. F3 · derivative.expiration_date: The restricted stock units were granted on March 1, 2016 and vest in four equal annual installments beginning on March 1, 2017. Read SEC document
March 01, 2017 Filed Mar 3, 2017 17:19 UTC	TESARO, Inc. TSRO · Entity 160894	Exercise / conversionCommon Stock	4,375	$0.00	$0.00	Disclosure SEC source: 0001104659-17-014116 · a4.xml · nonDerivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Exec. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.